Market Research Logo

North America Molecular Diagnostics Market Analysis by Product (Instruments, Reagents), by Test Location (Point-of-Care, Self-Test, Central Laboratories), by Technology (PCR, [Multiplex PCR], In Situ Hybridization, Isothermal Nucleic Acid Amplification Te

North America Molecular Diagnostics Market Analysis by Product (Instruments, Reagents), by Test Location (Point-of-Care, Self-Test, Central Laboratories), by Technology (PCR, [Multiplex PCR], In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology [INAAT], Chips & Microarrays, Mass Spectrometry, Sequencing, Transcription-mediated Amplification), by Application, Genetic Testing, Neurological Disease, Cardiovascular Disease, Microbiology, and Segment Forecasts to 2024

The North America molecular diagnostics market is expected to reach over USD 7.2 billion by 2024, according to a new report by Grand View Research, Inc. As a developed economy, North America has a well-equipped healthcare infrastructure. Moreover, the U.S. healthcare expenditure is projected to increase at a substantial rate over the forecast period.

Technological advancement in molecular diagnostic kits is expected to serve the as a primary driving force. Extensive R&D activities undertaken by the major companies for expansion of their product portfolio is another factor supporting growth. For instance, in 2015, a strategic collaboration was made between Sysmex Corporation and Laboratory Corporation in the field of blood-based molecular diagnostic tests to develop precision medicine in oncology.

Further Key Findings from the Report Suggest:

Reagents dominated the molecular diagnostics market with revenue of over USD 1.0 billion in 2015, owing to increasing R&D initiatives and as a result of discovery of novel biomarkers for cancer. Moreover, the fastest growing segment over the forecast period is also expected to be reagents, due to increasing adoption in the process of drug discovery.

In 2015, the largest shareholder by test location was central laboratories with around 60.0% share. The key attributes included expansion of healthcare facilities and presence of multiple clinical laboratory assays.

However, the point-of-care (PoC) segment is estimated to witness the most lucrative growth over the forecast period owing to development of fast and accurate diagnostic devices.

Infectious diseases contributed to the largest market revenue in 2015, as a result of new product development in the field of blood screening tests. HIV served as the largest market share rendering segment among infectious diseases.

The oncology segment is expected to grow at a lucrative double digit CAGR in the forecast period. This results from the high prevalence of cancer and greater opportunities in the field of cancer diagnostic tests for major players in North America.

On the basis of technology, polymerase chain reaction (PCR) dominated the market with USD 1.2 billion in 2015, owing to increasing applications of PCR in cancer tests

Sequencing is anticipated to be the fastest growing technology over the forecast period due to introduction of cost-effective and quick next-generation sequencing platforms for genetic diseases, cancer, and other chronic disorders.

The U.S. held the major share of the market in 2015 attributable to its developed economy and greater level of awareness amongst the population.

However, Canada is estimated to exhibit the fastest growth in terms of CAGR, owing to increasing prevalence of lifestyle diseases, such as cardiovascular diseases.

Some key players in the market include Abbott Laboratories; Roche Diagnostics; Hologic, Inc. (Gen Probe); Novartis AG; Bio-Rad laboratories, Inc.; Cepheid; Siemens Healthineers GmbH; Johnson & Johnson Services, Inc.; Bayer AG; Alere; bioMérieux SA; Sysmex Corporation; Becton, Dickinson and Company (BD); Danaher Corporation; Dako; and QIAGEN.

The strategies implemented by the participants include innovations through introduction of devices providing quick test results of blood samples and expansion to emerging markets.


Chapter 1 Executive Summary
Chapter 2 North America Molecular Diagnostics - Industry Outlook
2.1 Introduction
2.2 Market Segmentation
2.3 Market Size and Growth Prospects
2.4 Molecular Diagnostics - Market dynamics
2.4.1 Market driver analysis
2.4.1.1 Growing geriatric population base
2.4.1.2 Introduction of technological advancements
2.4.1.3 Increasing demand for point-of-care facilities
2.4.1.4 Growing prevalence of target diseases such as hospital acquired infections, genetic, cardiovascular and neurological diseases
2.4.1.5 External funding for executing research and development exercises
2.4.2 Market restraint analysis
2.4.2.1 Presence of ambiguous regulatory framework
2.4.2.2 High prices of molecular diagnostics tests
2.5 Key Opportunities Prioritized
2.6 Molecular Diagnostics - PESTEL Analysis
2.7 Molecular Diagnostics Market - Company Market Share Analysis, 2013
2.7.1 Recommendations for market participants
Chapter 3 North America Molecular Diagnostics Product Outlook
3.1 Molecular Diagnostics Revenue Share by Product, 2013 & 2024
3.2 Molecular Diagnostic Instruments Market
3.2.1 Molecular diagnostic instruments market, 2013 - 2024 (USD Million)
3.3 Molecular Diagnostic Reagents Market
3.3.1 Molecular diagnostic reagents market, 2013 - 2024 (USD Million)
3.4 Others
3.4.1 Other molecular diagnostic products market, 2013 - 2024 (USD Million)
Chapter 4 North America Molecular Diagnostics Test Location Outlook
4.1 Molecular Diagnostics Revenue Share by Test Location, 2013 & 2024
4.2 Molecular Diagnostic Point-of-Care Market
4.2.1 Molecular diagnostic point-of-care market, 2013 - 2024 (USD Million)
4.3 Molecular Diagnostics Self-Test or OTC Market
4.3.1 Self-test or OTC molecular diagnostics market, 2013 - 2024 (USD Million)
4.4 Molecular Diagnostic Central Laboratories Market
4.4.1 Molecular diagnostic central laboratories market, 2013 - 2024 (USD Million)
Chapter 5 North America Molecular Diagnostics Technology Outlook
5.1 Molecular Diagnostics Revenue Share by Technology, 2013 & 2024
5.2 Molecular Diagnostics Polymerase Chain Reaction (PCR) Market
5.2.1 Molecular diagnostics PCR market, 2013 - 2024 (USD Million)
5.2.2 Multiplex polymerase chain reaction-based Molecular diagnostics market
5.3 Molecular Diagnostics In-situ Hybridization Market
5.3.1 Molecular diagnostic in situ hybridization market, 2013 - 2024 (USD Million)
5.4 Molecular Diagnostics Isothermal Nucleic Acid Amplification Technology (INAAT) Market
5.4.1 Molecular INAAT Market, 2013 - 2024 (USD Million)
5.5 Molecular Diagnostics Chips and Microarrays Market
5.5.1 Molecular diagnostics chips and microarrays market, 2013 - 2024 (USD Million)
5.6 Molecular DIAGNOSTICS MASS SPECTROMETRY (MS) Market
5.6.1 Molecular diagnostics mass spectrometry market, 2013 - 2024 (USD Million)
5.7 Molecular Diagnostic Sequencing Market
5.7.1 Molecular diagnostic sequencing market, 2013 - 2024 (USD Million)
5.8 Molecular Diagnostics Transcription Mediated Amplification (TMA) Market
5.8.1 Molecular diagnostics TMA market, 2013 - 2024 (USD Million)
5.9 Molecular Diagnostic Other Technology Segments Market
5.9.1 Molecular diagnostic other technology segments market, 2013 - 2024 (USD Million)
Chapter 6 North America Molecular Diagnostics Application Outlook
6.1 Molecular Diagnostics Revenue Share, by Application, 2013 & 2024
6.2 Molecular Diagnostics-based Oncology Market
6.2.1 Molecular diagnostics-based oncology market, 2013 - 2024 (USD Million)
6.3 Molecular Diagnostic-based Pharmacogenomics Market
6.3.1 Molecular diagnostics-based Pharmacogenomics market, 2013 - 2024 (USD Million)
6.4 Molecular Diagnostics-based Infectious Diseases Market
6.4.1 Molecular diagnostics-based infectious diseases market, 2013 - 2024 (USD Million)
6.5 Molecular Diagnostics-based Genetic Testing Market
6.5.1 Molecular diagnostics-based genetic testing market, 2013 - 2024 (USD Million)
6.6 Molecular Diagnostics-based Neurological Diseases Market
6.6.1 Molecular diagnostics-based neurological diseases market, 2013 - 2024 (USD Million)
6.7 Molecular Diagnostics-based Cardiovascular Diseases Market
6.7.1 Molecular diagnostics-based cardiovascular diseases market, 2013 - 2024 (USD Million)
6.8 Molecular Diagnostics-Microbiology Market
6.8.1 Molecular diagnostics - Microbiology market, 2013 - 2024 (USD Million)
6.9 Molecular Diagnostics in Other Application Segments Market
6.9.1 Molecular Diagnostics in other application segments, 2013 - 2024 (USD Million)
Chapter 7 North America Molecular Diagnostics Regional Outlook
7.1 North America Molecular Diagnostics Revenue Share by Region, 2013 & 2024
7.2 U.S.
7.2.1 U.S. molecular diagnostics market, 2013 - 2024 (USD Million)
7.3 Canada
7.3.1 Canada molecular diagnostics market, 2013 - 2024 (USD Million)
Chapter 8 Competitive Landscape
8.1 Abbott Laboratories
8.1.1 Company overview
8.1.2 Financial performance
8.1.3 Product benchmarking
8.1.4 Strategic initiatives
8.2 Alere
8.2.1 Company overview
8.2.2 Financial performance
8.2.3 Product benchmarking
8.2.4 Strategic initiatives
8.3 Bayer AG
8.3.1 Company overview
8.3.2 Financial performance
8.3.3 Product benchmarking
8.3.4 Strategic initiatives
8.4 BD
8.4.1 Company overview
8.4.2 Financial performance
8.4.3 Product benchmarking
8.4.4 Strategic initiatives
8.5 bioMérieux SA
8.5.1 Company overview
8.5.2 Financial performance
8.5.3 Product benchmarking
8.5.4 Strategic initiatives
8.6 Bio-Rad Laboratories ‏
8.6.1 Company overview
8.6.2 Financial performance
8.6.3 Product benchmarking
8.6.4 Strategic initiatives
8.7 Cepheid
8.7.1 Company overview
8.7.2 Financial performance
8.7.3 Product benchmarking
8.7.4 Strategic initiatives
8.8 Dako
8.8.1 Company overview
8.8.2 Financial performance
8.8.3 Product benchmarking
8.8.4 Strategic initiatives
8.9 Danaher Corporation
8.9.1 Company overview
8.9.2 Financial performance
8.9.3 Product benchmarking
8.9.4 Strategic initiatives
8.10 Hologic, Inc. (Gen Probe)
8.10.1 Company overview
8.10.2 Financial performance
8.10.3 Product benchmarking
8.10.4 Strategic initiatives
8.11 Johnson & Johnson Services, Inc.
8.11.1 Company overview
8.11.2 Financial performance
8.11.3 Product benchmarking
8.11.4 Strategic initiatives
8.12 Novartis AG (Grifols)
8.12.1 Company overview
8.12.2 Financial performance
8.12.3 Product benchmarking
8.12.4 Strategic initiatives
8.13 Qiagen
8.13.1 Company overview
8.13.2 Financial performance
8.13.3 Product benchmarking
8.13.4 Strategic initiatives
8.14 Roche Diagnostics
8.14.1 Company overview
8.14.2 Financial performance
8.14.3 Product benchmarking
8.14.4 Strategic initiatives
8.15 Siemens Healthineers
8.15.1 Company overview
8.15.2 Financial performance
8.15.3 Product benchmarking
8.15.4 Strategic initiatives
8.16 Sysmex Corporation
8.16.1 Company overview
8.16.2 Financial performance
8.16.3 Product benchmarking
8.16.4 Strategic initiatives
Chapter 9 Methodology and Scope
9.1 Research Methodology
9.2 Research Scope & Assumptions
9.3 List of Data Sources
List of Tables
TABLE 1 North America molecular diagnostics market driver analysis
TABLE 2 North America molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 3 North America molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 4 North America molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 5 North America point-of-care (PCR) market, by segments, 2013 - 2024 (USD Million)
TABLE 6 North America molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 7 North America oncology market, by application, 2013 - 2024 (USD Million)
TABLE 8 North America infectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 9 North America genetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 10 U.S. molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 11 U.S. molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 12 U.S. molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 13 U.S. PCR market, by segments, 2013 - 2024 (USD Million)
TABLE 14 U.S. molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 15 U.S. oncology market, by application, 2013 - 2024 (USD Million)
TABLE 16 U.S. infectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 17 U.S. genetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 18 Canada molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 19 Canada molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 20 Canada molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 21 Canada PCR market, by segments, 2013 - 2024 (USD Million)
TABLE 22 Canada molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 23 Canada oncology market, by application, 2013 - 2024 (USD Million)
TABLE 24 Canada infectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 25 Canada genetic testing market, by application, 2013 - 2024 (USD Million)
List of Figures
FIG. 1 Market summary
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Penetration & growth prospect mapping
FIG. 6 SWOT Analysis, by factor (political & legal, economic and technological)
FIG. 7 Porter’s Five Forces Analysis
FIG. 8 Global percentage of population, by age group, 2000 and 2050
FIG. 9 General Trend of CLIA Waived Tests
FIG. 10 Average selling price range of diagnostic tests, 2013
FIG. 11 Company market share analysis - Molecular diagnostics market, 2013
FIG. 12 Recommendations for market participants
FIG. 13 North America molecular diagnostics market product outlook key takeaways
FIG. 14 North America molecular diagnostics market: product movement analysis
FIG. 15 North America instruments market, 2013 - 2024 (USD Million)
FIG. 16 North America reagents market, 2013 - 2024 (USD Million)
FIG. 17 North America other products market, 2013 - 2024 (USD Million)
FIG. 18 North America molecular diagnostics market test location outlook key takeaways
FIG. 19 North America molecular diagnostics market: test location movement analysis
FIG. 20 North America point-of-care market, 2013 - 2024 (USD Million)
FIG. 21 North America self-test or OTC market, 2013 - 2024 (USD Million)
FIG. 22 North America central laboratories market, 2013 - 2024 (USD Million)
FIG. 23 North America molecular diagnostics market technology outlook key takeaways
FIG. 24 North America molecular diagnostics market: technology movement analysis
FIG. 25 North America PCR market, 2013 - 2024 (USD Million)
FIG. 26 North America multiplex PCR market, 2013 - 2024 (USD Million)
FIG. 27 North America other PCR market, 2013 - 2024 (USD Million)
FIG. 28 North America in situ hybridization market, 2013 - 2024 (USD Million)
FIG. 29 North America INAAT market, 2013 - 2024 (USD Million)
FIG. 30 North America chips and microarrays market, 2013 - 2024 (USD Million
FIG. 31 North America MS market, 2013 - 2024 (USD Million)
FIG. 32 North America molecular diagnostic sequencing market, 2013 - 2024 (USD Million)
FIG. 33 North America TMA Market, 2013 - 2024 (USD Million)
FIG. 34 North America Others market, 2013 - 2024 (USD Million)
FIG. 35 North America molecular diagnostics market application outlook key takeaways
FIG. 36 North America molecular diagnostics market: application movement analysis
FIG. 37 North America oncology market, 2013 - 2024 (USD Million)
FIG. 38 North America Breast cancer market, 2013 - 2024 (USD Million)
FIG. 39 North America Prostate cancer market, 2013 - 2024 (USD Million)
FIG. 40 North America colorectal cancer market, 2013 - 2024 (USD Million)
FIG. 41 North America cervical cancer market, 2013 - 2024 (USD Million)
FIG. 42 North America kidney cancer market, 2013 - 2024 (USD Million)
FIG. 43 North America liver cancer market, 2013 - 2024 (USD Million)
FIG. 44 North America blood cancer market, 2013 - 2024 (USD Million)
FIG. 45 North America lung cancer market, 2013 - 2024 (USD Million)
FIG. 46 North America other market, 2013 - 2024 (USD Million)
FIG. 47 North America pharmacogenomics market, 2013 - 2024 (USD Million)
FIG. 48 North America infectious disease market, 2013 - 2024 (USD Million)
FIG. 49 North America MRSA market, 2013 - 2024 (USD Million)
FIG. 50 North America Clostridium difficile market, 2013 - 2024 (USD Million)
FIG. 51 North America vancomycin-resistant enterococci market, 2013 - 2024 (USD Million)
FIG. 52 North America carbapenem-resistant market, 2013 - 2024 (USD Million)
FIG. 53 North America flu market, 2013 - 2024 (USD Million)
FIG. 54 North America respiratory syncytial virus (RSV) market, 2013 - 2024 (USD Million)
FIG. 55 North America candida market, 2013 - 2024 (USD Million)
FIG. 56 North America tuberculosis and drug-resistant TB market, 2013 - 2024 (USD Million)
FIG. 57 North America meningitis market, 2013 - 2024 (USD Million)
FIG. 58 North America gastrointestinal panel testing market, 2013 - 2024 (USD Million)
FIG. 59 North America chlamydia market, 2013 - 2024 (USD Million)
FIG. 60 North America gonorrhea market, 2013 - 2024 (USD Million)
FIG. 61 North America HIV market, 2013 - 2024 (USD Million)
FIG. 62 North America hepatitis C market, 2013 - 2024 (USD Million)
FIG. 63 North America hepatitis B market, 2013 - 2024 (USD Million)
FIG. 64 North America other market, 2013 - 2024 (USD Million)
FIG. 65 North America genetic testing market, 2013 - 2024 (USD Million)
FIG. 66 North America newborn screening market, 2013 - 2024 (USD Million)
FIG. 67 North America predictive and presymptomatic testing market, 2013 - 2024 (USD Million)
FIG. 68 North America others market, 2013 - 2024 (USD Million)
FIG. 69 North America neurological diseases market, 2013 - 2024 (USD Million)
FIG. 70 North America cardiovascular diseases market, 2013 - 2024 (USD Million)
FIG. 71 North America microbiology market, 2013 - 2024 (USD Million)
FIG. 72 North America others market 2013 - 2024 (USD Million)
FIG. 73 North America molecular diagnostics market country outlook key takeaways
FIG. 74 North America molecular diagnostics market: country movement analysis
FIG. 75 U.S. molecular diagnostics market, 2013 - 2024 (USD Million)
FIG. 76 Canada molecular diagnostics market, 2013 - 2024 (USD Million)
FIG. 77 Strategy framework
FIG. 78 Participant categorization

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report